Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance @Cosmo_Pharma #HealthCare #OTC #OTCMarkets #OTCStocks #Investing

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results. Key highlights Health Tech: Upfront payment of $100 million received from Medtronic related to expansion of AI-driven partnership; Cosmo expects to receive an additional $100m from Medtronic this year linked to new services and the delivery of...


http://dlvr.it/TB0D1r

Comments

Popular posts from this blog

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Aurora Solar Technologies Corporate Update #AACTF #ACU.CA #ACU.V #AlternativeEnergy #AuroraSolarTech #CleanEnergy #CorporateUpdate #Energy #Investing #OTC #OTCMarkets #OTCStocks #RenewableEnergy #SmallCaps #Solar #TSXV

Coelacanth Announces Q3 2023 Financial and Operating Results #CEI.CA #CEI.V #CEIEF #Earnings #Investing #OTC #OTCMarkets #OTCStocks #Oil #OilAndGas #QuarterlyResults #Results #SmallCaps #TSXV